低kVp与低keV CT用于癌症患者阳性口服对比剂:一项随机临床试验
200例既往用钡剂口服对比剂行120 kVp腹盆CT的癌症监测成人随机接受标准浓度碘对比剂(7.2 g碘)或25%减量碘对比剂(5.4 g碘),行100 kVp或双能CT低keV(50-70 keV)扫描。减量碘对比剂在低kVp和低keV下肠腔衰减仍显著高于钡剂且肠管标记可接受,171/200例更偏好碘对比剂,钡剂组15例腹泻而碘对比剂组无腹泻。
要点
- 25%减量碘口服对比剂在100 kVp及50-65 keV下肠腔衰减仍高于120 kVp钡剂,肠管标记可接受。
- 碘对比剂与减量碘对比剂肠管充盈程度无差异,口味评分无差异(3.9±0.6)。
- 171/200例受试者偏好碘对比剂;钡剂组15例腹泻,碘对比剂组无腹泻。
核心结论
- 25%减量碘口服对比剂在低kVp和低keV CT上获得可接受的肠管标记,肠腔衰减显著高于120 kVp钡剂,且癌症治疗患者更偏好碘对比剂。
研究设计与样本
- 前瞻性临床试验纳入200例成人(97男、103女;平均年龄63岁±13),体重低于113 kg,2017年4月至2018年7月行肿瘤监测,既往曾用钡剂口服对比剂行120 kVp腹盆CT。随机分四组(每组50例):标准碘对比剂/100 kVp、减量碘对比剂/100 kVp、标准碘对比剂/双能CT、减量碘对比剂/双能CT;标准碘对比剂含碘7.2 g,减量碘对比剂含碘5.4 g;双能CT为80/140 kVp,重建50-70 keV虚拟单能图像。
关键影像表现/征象
- 所有CT图像质量均为可诊断(3.4±0.3,五分制)。
- 标准碘对比剂与减量碘对比剂肠管充盈程度无差异(P > .05)。
- 标准碘对比剂/100 kVp肠腔平均衰减459 HU±282,较钡剂/120 kVp的282 HU±73高78%。
- 标准碘对比剂50-65 keV肠腔衰减较钡剂高26%-121%(50 keV为626 HU±285,65 keV为356 HU±171)。
- 减量碘对比剂/100 kVp肠腔衰减385 HU±215,较钡剂高46%;50-65 keV较钡剂高19%-108%(50 keV为567 HU±270,65 keV为325 HU±156)(P < .05)。
诊断标准与关键数值
- 图像质量采用五分制评估,所有CT研究均为可诊断图像质量(3.4±0.3)。
- 肠管充盈范围与充盈均匀性分别采用四分制评估。
- 碘对比剂口味采用五分制评估,标准碘对比剂与减量碘对比剂间无差异(3.9±0.6)。
临床应用与阅片要点
- 在低kVp或双能CT低keV重建下,可将碘口服对比剂浓度降低25%仍获得可接受的肠管标记。
- 减量碘对比剂在100 kVp及50-65 keV下肠腔衰减仍高于120 kVp钡剂,阅片时可按低keV图像特点判读肠管充盈。
- 患者对碘对比剂偏好优于钡剂,钡剂组15例出现腹泻而碘对比剂组无腹泻。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Substantial gain in the attenuation of iodine on low-kVp and dual-energy CT processed low-keV virtual monochromatic images provides an opportunity for customization of positive oral contrast media administration. Purpose To perform an intrapatient comparison of bowel labeling, opacification, and taste preference with iodinated oral contrast medium (ICM) in standard (sICM) and 25%-reduced (rICM) concentrations at low tube voltage (100 kVp) or on low-energy (50-70 keV) virtual monochromatic images compared with barium-based oral contrast medium (BCM) at 120 kVp. Materials and Methods In this prospective clinical trial, 200 adults (97 men, 103 women; mean age, 63 years ± 13 [standard deviation]) who weighed less than 113 kg and who were undergoing oncologic surveillance (from April 2017 to July 2018) and who had previously undergone 120-kVp abdominopelvic CT with BCM randomly received sICM (7.2 g iodine) or rICM (5.4 g iodine) and underwent 100-kVp CT or dual-energy CT (80/140 kVp) scans to be in one of four groups (n = 50 each): sICM/100 kVp, rICM/100 kVp, sICM/dual-energy CT, and rICM/dual-energy CT. Qualitative analysis was performed for image quality (with a five-point scale), extent of bowel labeling, and homogeneity of opacification (with a four-point scale). Intraluminal attenuation of opacified small bowel was measured. A post-CT patient survey was performed to indicate contrast medium preference, taste of ICM (with a five-point scale), and adverse effects. Data were analyzed with analogs of analysis of variance. Results All CT studies were of diagnostic image quality (3.4 ± 0.3), with no difference in the degree of bowel opacification between sICM and rICM (P > .05). Compared with BCM/120 kVp (282 HU ± 73), mean attenuation was 78% higher with sICM/100 kVp (459 HU ± 282) and 26%-121% higher at sICM/50-65 keV (50 keV = 626 HU ± 285; 65 keV = 356 HU ± 171). With rICM, attenuation was 46% higher for 100 kVp (385 HU ± 215) and 19%-108% higher for 50-65 keV (50 keV = 567 HU ± 270; 65 keV = 325 HU ± 156) compared with BCM (P < .05). A total of 171 of 200 study participants preferred ICM to BCM, with no taste differences between sICM and rICM (3.9 ± 0.6). Fifteen participants had diarrhea with BCM, but none had diarrhea with ICM. Conclusion A 25%-reduced concentration of iodinated oral contrast medium resulted in acceptable bowel labeling while yielding substantially higher luminal attenuation at low-kVp and low-keV CT examinations with improved preference in patients undergoing treatment for cancer. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Laghi in this issue.
引用
- Parakh A, Negreros-Osuna AA, Patino M, et al. Low-keV and Low-kVp CT for Positive Oral Contrast Media in Patients with Cancer: A Randomized Clinical Trial. Radiology. 2019. PMID: 30964423. doi:10.1148/radiol.2019182393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。